Combining viruses with targeted cancer drugs boosts response
Two studies have uncovered how combining a reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies.
Researchers at The Institute of Cancer Research, London, have shown that this combination involving virotherapy can trigger powerful immune activation and cancer cell death, both in lab-grown cells and in mice.
The findings highlight how reprogramming how the tumour responds to stress and signals from the body’s immune system can unlock new therapeutic potential from existing drugs.
The oncolytic virus used in the two studies, called a reovirus, which was provided by Oncolytics Biotech for both studies, is a naturally occurring double-stranded RNA virus. It selectively infects and kills cancer cells, which have weakened antiviral defences – making them more vulnerable to infection.
In both studies, researchers utilised high-throughput drug screening to identify compounds that could enhance the effects of the reovirus. Two drugs – talazoparib and palbociclib – stood out as especially powerful partners for the virus, each working in a different way to boost its cancer-killing effects.
Immune activation
In the talazoparib study, the reovirus activated a protein called PARP-1, which normally helps cells survive stress. Talazoparib, a PARP-1 inhibitor, disrupted the cancer cells’ defences, triggering stronger cell death and immune activation.
The combination was also seen to amplify the production of key immune-stimulating molecules. In mouse models, this dual therapy not only shrank tumours but also prevented their return.
Meanwhile, the palbociclib study revealed that the drug enhances reovirus-induced endoplasmic reticulum stress – a form of cellular stress that can trigger immune activation. The combination boosts production of immune-stimulating molecules, increasing the expression level of antigen-presenting molecules and altering the peptides associated with them.
These changes made cancer cells more visible to the immune system and led to a stronger infiltration of immune cells. In mouse models, the combination also led to reduced tumour growth and increased immune cell activity.
Both studies highlight the importance of pattern recognition receptors – which detect viral RNA and initiate immune responses to help the body recognise and attack cancer cells – such as RIG-I.
Reovirus activates RIG-I, and both talazoparib and palbociclib appear to enhance the immune response – either by blocking a protective molecule that helps cancer cells survive (in the case of talazoparib) or by amplifying stress signals (palbociclib).
Importantly, the research team showed that similar effects could be achieved using non-viral RNA therapies and molecules that activate RIG-I, suggesting that the therapeutic benefits of these combinations could extend beyond reovirus itself.
Testing the combination in clinical trials
Both talazoparib and palbociclib are already approved for use in certain cancers, such as breast cancer, and the Type 3 (Dearing) strain of reovirus is currently under clinical investigation.
The research team are now exploring how these combinations of reoviruses and targeted therapies could be tested in early-phase clinical trials, potentially alongside immune checkpoint inhibitors.
Co-first author of both studies Dr Victoria Roulstone, Senior Scientific Officer in the Targeted Therapy Group at the ICR, said: “This work highlights the power of combining virotherapy with targeted drugs that modulate the tumour environment – unlocking entirely new ways to kill cancer. It’s an exciting step towards more personalised and immune-driven cancer treatments and I hope we’re able to see these discoveries turned into early-stage clinical trials to test whether these combinations work just as effectively in patients.”
Diana Turner, Senior Digital Content Editor, DDW
